ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
Mace-Like Plasmonic Au-Pd Heterostructures Boost Near-Infrared Photoimmunotherapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 42 citations in OpenAlex.
- Review
- A smart amphiphilic nanoplatform amplifies ROS-mediated immunogenic cell death to suppress bladder cancer growth and metastasis.Journal of nanobiotechnology · 2025Article
- Nicotine Attenuates Pathogenesis of Parkinson's Disease via α7-nAChR-Mediated Lipid Metabolic Reprogramming and Anti-inflammatory Signaling.Molecular neurobiology · 2025Article
- An Anisotropic Gold-Palladium Heterostructured Nanosystem for Synergistically Overcoming Radioresistance and Enhancing Melanoma Radioimmunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Nanomaterials in PCR: exploring light-to-heat conversion mechanisms and microfluidic integration.Microsystems & nanoengineering · 2025Review
- Dual-Activatable Nano-Immunomodulator for NIR-II Fluorescence Imaging-Guided Precision Cancer Photodynamic Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- The marine-derived compound TAG alleviates Parkinson's disease by restoring RUBCN-mediated lipid metabolism homeostasis.Acta pharmacologica Sinica · 2024Article
- Manipulating calcium homeostasis with nanoplatforms for enhanced cancer therapy.Exploration (Beijing, China) · 2024Review
- Review
- Photothermal Nanomaterials: A Powerful Light-to-Heat Converter.Chemical reviews · 2023Review
- Cerium End-Deposited Gold Nanorods-Based Photoimmunotherapy for Boosting Tumor Immunogenicity.Pharmaceutics · 2023Article
- Mace-Like Plasmonic Au-Pd Heterostructures Boost Near-Infrared Photoimmunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Photoimmunotherapy, with spatiotemporal precision and noninvasive property, has provided a novel targeted therapeutic strategy for highly malignant triple-negative breast cancer (TNBC). However, their therapeutic effect is severely restricted by the insufficient generation of tumor antigens and the weak activation of immune response, which is caused by the limited tissue penetration of light and complex immunosuppressive microenvironment. To improve the outcomes, herein, mace-like plasmonic AuPd heterostructures (Au Pd HSs) have been fabricated to boost near-infrared (NIR) photoimmunotherapy. The plasmonic Au Pd HSs exhibit strong photothermal and photodynamic effects under NIR light irradiation, effectively triggering immunogenic cell death (ICD) to activate the immune response. Meanwhile, the spiky surface of Au Pd HSs can also stimulate the maturation of DCs to present these antigens, amplifying the immune response. Ultimately, combining with anti-programmed death-ligand 1 (α-PD-L1) will further reverse the immunosuppressive microenvironment and enhance the infiltration of cytotoxic T lymphocytes (CTLs), not only eradicating primary TNBC but also completely inhibiting mimetic metastatic TNBC. Overall, the current study opens a new path for the treatment of TNBC through immunotherapy by integrating nanotopology and plasmonic performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.